逼尿肌无力的治疗进展  

Progress in treatment of detrusor underactivity

作　　者：朱晓雨[1] 陶方泽(综述)[1] 王安喜(审校)[1] ZHU Xiaoyu;TAO Fangze;WANG Anxi(Department of Urology,Nanjing Hospital of TCM Affiliated to Nanjing University of Chinese Medicine,Nanjing 210000,China)

机构地区：[1]南京中医药大学附属南京市中医院泌尿外科,江苏南京210000

出　　处：《西部医学》2023年第11期1711-1716,共6页Medical Journal of West China

基　　金：南京市中医药青年人才培养计划(宁卫中医【2020】4号,ZYQ20005)。

摘　　要：逼尿肌无力(DU)主要分为特发性、神经源性和肌源性,是一项复杂的、多因素的病理过程,发病率随着年龄提升,严重危害中老年人的生活质量,但其具体发病机制尚不明确,也缺乏一套有效的、标准化的治疗方案,尚属于泌尿外科较为偏僻的领域。近年来,其治疗也随着DU研究的不断深入而有所进步。目前常用的治疗方法包括康复治疗、药物治疗、手术治疗、干细胞基因治疗以及中医药治疗,但单一手段的疗效往往不尽如人意。本综述通过查阅近几年相关文献,对现阶段临床上治疗DU的方案进行总结,旨在为临床上有效治疗DU提供参考。Detrusor asthenia(DU),which is mainly divided into idiopathic,neurogenic and myogenic,is a complex and multi-factor pathological process,and its incidence increases with age,which seriously affects the quality of life of middle-aged and elderly people.However,its specific pathogenesis is still unclear,and there is a lack of an effective and standardized treatment plan,and it still belongs to the relatively remote field of urology.In recent years,its treatment has been improved with the continuous deepening of DU research.At present,the commonly used treatment methods include rehabilitation therapy,drug therapy,surgery,stem cell gene therapy and traditional Chinese medicine therapy,but the effect of a single means is often unsatisfactory.By referring to the relevant literature in recent years,this review summarizes the current clinical treatment of DU,and provides references for effective clinical treatment of DU.

关 键 词：逼尿肌无力 神经源性膀胱 治疗 进展 

分 类 号：R694[医药卫生—泌尿科学]